February 12, 2026 09:25 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues

India to begin human trials of COVAXIN next week

| @indiablooms | Jul 07, 2020, at 01:22 pm

New Delhi/IBNS: The human trials of India's first Covid-19 vaccine, COVAXIN, is expected to begin next week, media reports said.

COVAXIN, which has been developed by Hyderabad-based Bharat Biotech International Limited (BBIL), will be tested on more than 1,100 people in phase 1 and 2 clinical trials.

COVAXIN was caught in the midst of a controversy after the Indian Council of Medical Research (ICMR) had partnered with BBIL to fast-track the clinical trials to launch India's indigenous vaccine by Aug 15.

The Indian scientific community has, however, termed the ICMR's claim to produce the Covid-19 vaccine by Aug 15 as "risky" and "impossible".

AIIMS director Randeep Guleria, who is the head of the clinical research group of the national task force on Covid, told The Indian Express, "It will be a very challenging and difficult task, considering that we have to look at both efficacy and safety of any vaccine that is introduced.

"Also, if we get the desired results, the other challenge is the process of mass production of the vaccine."

Virologist Shaheed Jameel, the chief executive of the Wellcome Trust-DBT Alliance that funds health research in India, said as quoted by the daily, "I fear the global scientific community would be laughing at us for this. It should not have happened. India is a serious player in science."

"Who is going to trust us if we behave like this? Who is going to believe us even if we indeed come up with a good vaccine tomorrow?… And I am appalled at the kind of language used in the letter. It is not a letter, it reads like a threat," he added.

Defending the claim, the ICMR said the process was “in accordance with the globally accepted norms to fast-track the vaccine development."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.